Iñigo López-Huerta Anitua
Director Financiero/CFO en Ysios Capital Partners SGEIC SA .
Origen de la red de primer grado Iñigo López-Huerta Anitua.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.
20
| Private Company | Investment Managers | 20 |
University of Deusto
15
| College/University | Other Consumer Services | 15 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Iñigo López-Huerta Anitua a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
TIGENIX NV | Medical Specialties | Director/Board Member Director of Finance/CFO | |
KALA BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
ATRECA, INC. | Biotechnology | Director/Board Member | |
NURIX THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
BBVA | Major Banks | Director/Board Member Corporate Officer/Principal | |
Talde Gestión SGEIC SA
Talde Gestión SGEIC SA Investment ManagersFinance Talde Gestión SGEIC SA (Talde Gestión) is a private equity firm founded in 1976. The firm is headquartered in Bilbao, Spain. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Aelix, Inc.
Aelix, Inc. Internet Software/ServicesTechnology Services Part of Billing Services Group Ltd., Aelix, Inc. provides intelligent communications solutions to enterprises, notably in the travel and hospitality, financial services, and electronic commerce sectors. The company is based in Los Angeles, CA. Aelix was acquired by Avery Communications, Inc. from ComF5 International, Inc. on December 04, 2001 for $4.10 million. | Internet Software/Services | Director/Board Member | |
The University of Colorado | College/University | Undergraduate Degree | |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
University of Barcelona | College/University | Doctorate Degree Undergraduate Degree | |
Universitat Pompeu Fabra | College/University | Graduate Degree Graduate Degree | |
Universität Konstanz | College/University | Doctorate Degree | |
Escuela Superior de Administración y Dirección de Empresas | College/University | Graduate Degree Corporate Officer/Principal | |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | President | |
Altamar Private Equity SGIIC SA /Private Equity/
Altamar Private Equity SGIIC SA /Private Equity/ Investment ManagersFinance Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile. | Investment Managers | Private Equity Investor | |
BANCO SANTANDER, S.A. | Major Banks | Corporate Officer/Principal Private Equity Analyst | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman Director of Finance/CFO | |
Universidad Autónoma de Madrid | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Founder | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Jewish Hospital
Jewish Hospital Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million. | Hospital/Nursing Management | Corporate Officer/Principal | |
Mckinsey & Co., Inc. (Switzerland) | Corporate Officer/Principal | ||
LLEIDANETWORKS SERVEIS TELEMÀTICS, S.A. | Wireless Telecommunications | Director of Finance/CFO | |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member | |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
Medlumics SL
Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman Director/Board Member | |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder | |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
The University of Colorado School of Medicine | College/University | Doctorate Degree | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
UNITY BIOTECHNOLOGY, INC. | Biotechnology | Director/Board Member | |
ARCUS BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services The Parker Institute for Cancer Immunotherapy is a research organization that aims to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. The Parker Institute for Cancer Immunotherapy is based in San Francisco, CA. The private company conducts clinical trials to tackle the toughest cancers and answer the hardest questions in immunotherapy. The institute coordinates cancer research efforts between the best scientists, clinicians, and partners in the industry. The company has legal experts who help their researchers navigate the intellectual property process and turn their cancer immunotherapy discoveries into treatments. It was founded by Sean N. Parker, Adam Kolom, Michael Polansky. | Miscellaneous Commercial Services | Director/Board Member | |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
CytoKi Pharma ApS
CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
TANGO THERAPEUTICS, INC. | Biotechnology | Founder | |
Kalthera, Inc.
Kalthera, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Immpact Bio USA, Inc., Kalthera, Inc. provides progressive clinical trials services. The company is based in Westlake Village, CA. The company was founded by Yvonne Chen, Cristina Puig Saus, Jim Johnston, Antoni Ribas. Jim Johnston has been the CEO since incorporation. Kalthera was acquired by Immpact Bio USA, Inc. on July 22, 2021. | Miscellaneous Commercial Services | Founder | |
Universidad Pontificia Comillas | College/University | Graduate Degree Graduate Degree Graduate Degree |
Estadísticas
Internacional
España | 19 |
Estados Unidos | 18 |
Suiza | 6 |
Alemania | 3 |
Dinamarca | 3 |
Sectorial
Health Technology | 30 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 5 |
Technology Services | 2 |
Operativa
Director/Board Member | 162 |
Corporate Officer/Principal | 40 |
Private Equity Investor | 29 |
Chairman | 28 |
Independent Dir/Board Member | 27 |
Las relaciones más conectadas
- Bolsa de valores
- Insiders
- Iñigo López-Huerta Anitua
- Conexiones Empresas